GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Asset Turnover

Turnstone Biologics (Turnstone Biologics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Turnstone Biologics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Turnstone Biologics's Total Assets for the quarter that ended in Mar. 2024 was $103.60 Mil. Therefore, Turnstone Biologics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Turnstone Biologics's annualized ROE % for the quarter that ended in Mar. 2024 was -87.89%. It is also linked to ROA % through Du Pont Formula. Turnstone Biologics's annualized ROA % for the quarter that ended in Mar. 2024 was -75.79%.


Turnstone Biologics Asset Turnover Historical Data

The historical data trend for Turnstone Biologics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turnstone Biologics Asset Turnover Chart

Turnstone Biologics Annual Data
Trend Dec21 Dec22 Dec23
Asset Turnover
0.54 0.49 0.17

Turnstone Biologics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 - - - -

Competitive Comparison of Turnstone Biologics's Asset Turnover

For the Biotechnology subindustry, Turnstone Biologics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turnstone Biologics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Turnstone Biologics's Asset Turnover falls into.



Turnstone Biologics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Turnstone Biologics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=19.306/( (114.938+112.815)/ 2 )
=19.306/113.8765
=0.17

Turnstone Biologics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (112.815+94.39)/ 2 )
=0/103.6025
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Turnstone Biologics  (NAS:TSBX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Turnstone Biologics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-78.516/89.339
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-78.516 / 0)*(0 / 103.6025)*(103.6025/ 89.339)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1597
=ROA %*Equity Multiplier
=-75.79 %*1.1597
=-87.89 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Turnstone Biologics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-78.516/103.6025
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-78.516 / 0)*(0 / 103.6025)
=Net Margin %*Asset Turnover
= %*0
=-75.79 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Turnstone Biologics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Turnstone Biologics (Turnstone Biologics) Business Description

Traded in Other Exchanges
N/A
Address
9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Executives
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah director, officer: President & CEO C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat officer: Chief Business Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan officer: Chief Financial Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr. officer: Chief Legal Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu officer: Int. Chief Technology Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess director, officer: Interim Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot officer: Chief Scientific Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037